RxDoctor Payments Data

Tia Nelson, DO

Family Medicine · Norfolk, VANPI 1689171175

Payments from drug & device makers

$1,512in general payments, 2019–2025

Across 45 payments — averaging $33.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$773
  • Novo Nordisk$277
  • AbbVie$192
  • Lilly USA, LLC$64
  • Pfizer$57
  • Exact Sciences$36
  • plus $112 from 7 others

What the payments were for

  • Food & beverage$1,512100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,512 in reported general payments places this provider in the 70th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$46,030
Medicare patients
90
Services billed
620

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin50$52,728
OzempicSemaglutide36$48,500
JanuviaSitagliptin Phosphate39$38,478
TrulicityDulaglutide17$27,409
EliquisApixaban22$26,274
FarxigaDapagliflozin Propanediol16$23,847
XareltoRivaroxaban27$21,814
RybelsusSemaglutide12$19,499
MounjaroTirzepatide12$18,237
Lantus SolostarInsulin Glargine,hum.Rec.Anlog22$3,428
Atorvastatin Calcium259$2,256
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate12$2,008
Amlodipine Besylate282$1,830
Colchicine30$1,498
Omeprazole72$1,292

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$277$67,99948 claims
Lilly USA, LLCTrulicity, Mounjaro$64$45,64629 claims
PfizerEliquis$57$26,27422 claims
AstraZenecaFarxiga$773$23,84716 claims
Johnson & JohnsonXarelto$15$21,81427 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Norfolk

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →